{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T23:02:20Z","timestamp":1766444540034,"version":"3.48.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,22]]},"DOI":"10.7759\/cureus.99868","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T22:59:38Z","timestamp":1766444378000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Rituximab and Cyclophosphamide for Induction Therapy in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Systematic Review of Randomized Trials and Comparative Cohort Evidence"],"prefix":"10.7759","author":[{"given":"Sheharyar Hassan","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Zahid","family":"Manzoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136065","article-title":"Immunopathology of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"26","author":"Lisowska KA","year":"2025","unstructured":"Lisowska KA, Wardowska A. Immunopathology of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Int J Mol Sci. 2025, 26:6065. 10.3390\/ijms26136065","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.24","article-title":"Antineutrophil cytoplasm antibody-associated vasculitis: recent developments","volume":"84","author":"Furuta S","year":"2013","unstructured":"Furuta S, Jayne DR. Antineutrophil cytoplasm antibody-associated vasculitis: recent developments. Kidney Int. 2013, 84:244-9. 10.1038\/ki.2013.24","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102953","article-title":"Old known and possible new biomarkers of ANCA-associated vasculitis","volume":"133","author":"Scurt FG","year":"2022","unstructured":"Scurt FG, Bose K, Hammoud B, et al.. Old known and possible new biomarkers of ANCA-associated vasculitis. J Autoimmun. 2022, 133:102953. 10.1016\/j.jaut.2022.102953","journal-title":"J Autoimmun"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026733","article-title":"Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement: a comparative cohort study","volume":"100","author":"Speer C","year":"2021","unstructured":"Speer C, Altenm\u00fcller-Walther C, Splitthoff J, et al.. Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement: a comparative cohort study. Medicine (Baltimore). 2021, 100:e26733. 10.1097\/MD.0000000000026733","journal-title":"Medicine (Baltimore)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.11.121","article-title":"The applications of anti-CD20 antibodies to treat various B cells disorders","volume":"109","author":"Payandeh Z","year":"2019","unstructured":"Payandeh Z, Bahrami AA, Hoseinpoor R, et al.. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019, 109:2415-26. 10.1016\/j.biopha.2018.11.121","journal-title":"Biomed Pharmacother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/life14101223","article-title":"Mechanisms of resistance to rituximab used for the treatment of autoimmune blistering diseases","volume":"14","author":"Popa LG","year":"2024","unstructured":"Popa LG, Dumitras I, Giurcaneanu C, et al.. Mechanisms of resistance to rituximab used for the treatment of autoimmune blistering diseases. Life (Basel). 2024, 14:1223. 10.3390\/life14101223","journal-title":"Life (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone JH","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al.. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010, 363:221-32. 10.1056\/NEJMoa0909905","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones RB","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, et al.. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010, 363:211-20. 10.1056\/NEJMoa0909169","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151063","article-title":"The Birmingham Vasculitis Activity Score as a measure of disease activity in patients with giant cell arteritis","volume":"43","author":"Kermani TA","year":"2016","unstructured":"Kermani TA, Cuthbertson D, Carette S, et al.. The Birmingham Vasculitis Activity Score as a measure of disease activity in patients with giant cell arteritis. J Rheumatol. 2016, 43:1078-84. 10.3899\/jrheum.151063","journal-title":"J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi SA","year":"2024","unstructured":"Nejadghaderi SA, Balibegloo M, Rezaei N. The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons. Health Sci Rep. 2024, 7:e2165. 10.1002\/hsr2.2165","journal-title":"Health Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks U","year":"2013","unstructured":"Specks U, Merkel PA, Seo P, et al.. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013, 369:417-27. 10.1056\/NEJMoa1213277","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43799","article-title":"Rituximab vs cyclophosphamide induction therapy for patients with granulomatosis with polyangiitis","volume":"5","author":"Pu\u00e9chal X","year":"2022","unstructured":"Pu\u00e9chal X, Iudici M, Perrodeau E, et al.. Rituximab vs cyclophosphamide induction therapy for patients with granulomatosis with polyangiitis. JAMA Netw Open. 2022, 5:e2243799. 10.1001\/jamanetworkopen.2022.43799","journal-title":"JAMA Netw Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/art.42388","article-title":"Autoreactive plasmablasts after B cell depletion with rituximab and relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"75","author":"Berti A","year":"2023","unstructured":"Berti A, Hillion S, Konig MF, et al.. Autoreactive plasmablasts after B cell depletion with rituximab and relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2023, 75:736-47. 10.1002\/art.42388","journal-title":"Arthritis Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad197","article-title":"Sustained post-rituximab B-cell depletion is common in ANCA-associated vasculitis and is affected by sex and renal function","volume":"39","author":"Mescia F","year":"2024","unstructured":"Mescia F, Salviani C, Tonoli M, et al.. Sustained post-rituximab B-cell depletion is common in ANCA-associated vasculitis and is affected by sex and renal function. Nephrol Dial Transplant. 2024, 39:683-93. 10.1093\/ndt\/gfad197","journal-title":"Nephrol Dial Transplant"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105768","article-title":"Update on targeted treatments for ANCA-associated vasculitis","volume":"92","author":"Pu\u00e9chal X","year":"2025","unstructured":"Pu\u00e9chal X. Update on targeted treatments for ANCA-associated vasculitis. Joint Bone Spine. 2025, 92:105768. 10.1016\/j.jbspin.2024.105768","journal-title":"Joint Bone Spine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001030","article-title":"Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis","volume":"25","author":"McClure ME","year":"2019","unstructured":"McClure ME, Wason J, Gopaluni S, Tieu J, Smith RM, Jayne DR, Jones RB. Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis. J Clin Rheumatol. 2019, 25:217-23. 10.1097\/RHU.0000000000001030","journal-title":"J Clin Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5534851","article-title":"Update in the management of ANCA-associated vasculitis: recent developments and future perspectives","volume":"2021","author":"Samman KN","year":"2021","unstructured":"Samman KN, Ross C, Pagnoux C, Makhzoum JP. Update in the management of ANCA-associated vasculitis: recent developments and future perspectives. Int J Rheumatol. 2021, 2021:5534851. 10.1155\/2021\/5534851","journal-title":"Int J Rheumatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.185710","article-title":"A comparative effectiveness research of azathioprine and cyclophosphamide on the clinical and serological response in pemphigus vulgaris","volume":"61","author":"Sardana K","year":"2016","unstructured":"Sardana K, Agarwal P, Bansal S, Uppal B, Garg VK. A comparative effectiveness research of azathioprine and cyclophosphamide on the clinical and serological response in pemphigus vulgaris. Indian J Dermatol. 2016, 61:418-26. 10.4103\/0019-5154.185710","journal-title":"Indian J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224623","article-title":"Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials","volume":"83","author":"Delestre F","year":"2024","unstructured":"Delestre F, Charles P, Karras A, et al.. Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis. 2024, 83:233-41. 10.1136\/ard-2023-224623","journal-title":"Ann Rheum Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14010208","article-title":"How we treat ANCA-associated vasculitis: a focus on the maintenance therapy","volume":"14","author":"Roccatello D","year":"2025","unstructured":"Roccatello D, Fenoglio R, De Simone E, Sciascia S. How we treat ANCA-associated vasculitis: a focus on the maintenance therapy. J Clin Med. 2025, 14:208. 10.3390\/jcm14010208","journal-title":"J Clin Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-017-0082-y","article-title":"Avoidance of harm from treatment for ANCA-associated vasculitis","volume":"3","author":"King C","year":"2017","unstructured":"King C, Harper L. Avoidance of harm from treatment for ANCA-associated vasculitis. Curr Treatm Opt Rheumatol. 2017, 3:230-43. 10.1007\/s40674-017-0082-y","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/joim.70024","article-title":"Long-term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA-associated vasculitis in multicenter REVEAL cohort study","volume":"298","author":"Matsuda S","year":"2025","unstructured":"Matsuda S, Kotani T, Nishioka D, et al.. Long-term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA-associated vasculitis in multicenter REVEAL cohort study. J Intern Med. 2025, 298:504-15. 10.1111\/joim.70024","journal-title":"J Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/444640-comparison-of-rituximab-and-cyclophosphamide-for-induction-therapy-in-antineutrophil-cytoplasmic-antibody-anca-associated-vasculitis-a-systematic-review-of-randomized-trials-and-comparative-cohort-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T22:59:38Z","timestamp":1766444378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/444640-comparison-of-rituximab-and-cyclophosphamide-for-induction-therapy-in-antineutrophil-cytoplasmic-antibody-anca-associated-vasculitis-a-systematic-review-of-randomized-trials-and-comparative-cohort-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.99868","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}